Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

By D. Franz, J. Leonard, C. Tudor, G. Chuck, Marguerite M. Caré, G. Sethuraman, A. Dinopoulos, G. Thomas, K. Crone. Annals of Neurology, 2006

600 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/3f0bf994b5e29a68693d1cc3c432844ca497ec19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Daniel C. Alexander
2. Darcy A. Krueger
3. Hope Northrup

In Oncology

1. David M. Sabatini
2. D. Guertin

In Physiology

1. David M. Sabatini
2. Darcy A. Krueger
3. Hope Northrup

Citations in the corpus

• Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference (2013, background): “Twelve subcommittees, each led by a clinician with advanced expertise in TSC and the relevant medical subspecialty, were organized to focus on specific disease focus topics that have important clinical management implications in TSC: (1) dermatology and dentistry; (2) nephrology; (3) pulmonology; (4”
• Defining the role of mTOR in cancer. (2007, background): “Clinical trials with rapamycin are underway for treating some of these conditions and early reports from TSC trials indicate promising successes (Franz et al., 2006).”
• Multi-compartment microscopic diffusion imaging (2016, background): “Our findings have clear translational significance as SMT may help oversee treatment success in promising clinical trials (Franz et al., 2006; Bissler et al., 2008; Krueger et al., 2010; Tillema et al., 2012) where patients receive mTOR inhibitors such as everolimus and sirolimus.”
• mTOR and cancer: insights into a complex relationship (2006, background): “In a recent clinical trial rapamycin reduced the sizes of the astrocytomas that are frequently seen in patients with TS”
• Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex (2008, background): “reduced cell size.(14) In the Tsc1CKO mice, although late treatment did not necessarily reverse the increased brain size and astrogliosis back to control levels, early and late treatment with rapamycin was clearly effective in preventing further progression of astrocyte proliferation and brain growt”
• Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference (2013, neutral): “The individual panels were organized as follows: (1) dermatology and dentistry; (2) ophthalmology; (3) brain structure, tubers, and tumors; (4) epilepsy; (5) TSC-associated neuropsychiatric disorders; (6) cardiology; (7) pulmonology; (8) nephrology; (9) endocrinology; (10) gastroenterology; and (11)”